title: Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor.
abstract: It is well known that bronchial asthma is defined as chronic eosinophilic inflammation of the respiratory tract and that as one of the various types of inflammatory cells, eosinophils induce the airway inflammation of chronic asthma. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to play an important role in the prolongation of the survival of eosinophils. We investigated the inhibitory effect of the selective phosphodiesterase (PDE) 4 inhibitors, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[1,2-i]purin-5-one (XT-611) and rolipram, and the nonselective PDE inhibitor theophylline, against GM-CSF-induced prolongation of the survival of eosinophils isolated from patients with bronchial asthma. Eosinophils (10(6) cells/ml) were incubated in the presence of GM-CSF together with or without theophylline, rolipram or XT-611 at 37 degrees C, and the viable cells were assessed up to 4d using Trypan blue dye exclusion. The presence of theophylline (10(-4) M), rolipram (10(-4)-10(-5) M) or XT-611 (10(-4)-10(-5) M) significantly reduced the GM-CSF (10 pg/ml)-induced prolongation of viability of eosinophils. These findings suggest that selective PDE 4 inhibitors, including XT-611, may effectively reduce the activities of inflammatory cells in the airway of bronchial asthma patients.
authors.affiliation: Second Department of Internal Medicine and Laboratory Medicine, Nagoya University School of Medicine, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Tatsumi
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Kitaichi
authors.forename: Kenji
authors.initials: K
authors.lastname: Baba
authors.forename: Ryujiro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Eiji
authors.initials: E
authors.lastname: Shibata
authors.forename: Kenji
authors.initials: K
authors.lastname: Takagi
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Takaaki
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Kenzo
authors.initials: K
authors.lastname: Takagi
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D004804:Eosinophils / Q000187:drug effects* / Q000502:physiology; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011687:Purines / Q000494:pharmacology*; D020889:Rolipram / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology
chemical_list: C461440:3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo(1,2-i)purin-5-one; D010726:Phosphodiesterase Inhibitors; D011687:Purines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013806:Theophylline; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram